Frontiers in Immunology | |
Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma | |
Cui Chen2  Hang Yang3  Man Nie3  Kang-Ming Huang3  Xiao-Qing Sun3  Xiao-Hua He3  Jia-Jia Huang3  Zhi-Ming Li3  Peng Sun3  Yu Wang3  | |
[1] Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China;Department of Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China;State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; | |
关键词: natural killer/T cell lymphoma; anlotinib; anti-PD-1 antibody; pegaspargase; radiotherapy; | |
DOI : 10.3389/fimmu.2022.766200 | |
来源: DOAJ |
【 摘 要 】
Asparaginase/pegaspargase containing regimens combined with radiotherapy are highly effective and considered the cornerstone of localized Natural killer/T-cell lymphoma (NKTL) treatment. However, these chemotherapy regimens inevitably cause relatively high incidence of treatment-related adverse events (TRAEs). Herein we retrospectively evaluated the efficacy and safety of the combined regimen of anti-PD-1 antibody, anlotinib and pegaspargase “sandwich” with radiotherapy in localized NKTL. Anti-PD-1 antibody and pegaspargase at 2500 U/m2 were administered on day 1, while anlotinib (12 mg once a day) was orally administered on days 1-14. The treatment was repeated every 3 weeks. All the eight patients included received 3 cycles of the regimen followed by radiotherapy and an additional 3 cycles. The overall response rate was 100%, and the complete response rate was 87.5%. With a median follow-up time of 35.5 months (range, 34.03-40.90 months), median PFS and OS times were not reached. The 3-year PFS and OS rates were 100% and 100%, respectively. All patients were alive at the last follow-up. No treatment-related death and no grade 4 TRAE was reported. No grade 3/4 hematological toxicity was detected, and half of the patients didn’t report any hematological toxicity. This study indicates that anti-PD-1 antibody combined with anlotinib and pegaspargase is a promising chemoradiotherapy regimen for localized NTKL, with mild toxicity and good tolerance.
【 授权许可】
Unknown